Laxou

People with mental disorders often face stigma from others, which can lead to self-isolation and difficulty in receiving care and recovering. This stigma can be internalized as self-stigma, causing emotional distress like shame and making it harder for individuals to cope and adhere to treatment. Reducing self-stigma and shame is important to lessen the challenges associated with mental illness. Compassion Focused Therapy (CFT), a type of cognitive behavioral therapy, aims to reduce shame and improve self-compassion, which may help improve symptoms and resilience. However, its effectiveness in people with high self-stigma has not been tested before. The study compares the effects of group-based Compassion Focused Therapy to treatment as usual and a psychoeducation program called Ending Self Stigma (ESS). CFT involves experiential activities, education about compassion and emotional regulation, and guided exercises both during sessions and at home. ESS includes sessions on understanding stigma and changing negative self-thoughts, with home practice assignments to boost self-esteem and goal achievement. Participants receive these interventions to see which most effectively reduces self-stigma. Participants will be assessed at the start and then monthly for three months using the Internalized Stigma of Mental Illness inventory to measure changes in self-stigma. The study involves multiple centers and random assignment to groups. Researchers will monitor participants' progress, adherence to the programs, and evaluate the acceptability and impact of the therapies. This will help determine how well these approaches work to reduce internalized stigma in people with mental health conditions.

Researchers are evaluating a Mobile Perinatal Psychiatry Team (EMPPer) designed to support children aged 0 to 3 years and their parents who face psycho-social vulnerabilities and difficulty accessing psychiatric care. This team provides home interventions aimed at improving parent-child interactions and preventing developmental issues. The study compares the effect of EMPPer on the rate of psychomotor development abnormalities at age 2 years with similar regions without this service and with data from before EMPPer was introduced. The intervention involves the EMPPer team visiting families in need to facilitate easier access to psychiatric care and early detection of developmental and interaction disorders. The study includes children from the EMPPer service region and comparison regions (Reims and Strasbourg), with data collected at 24 months and again at 3 to 4 years. The study also evaluates the implementation process, intervention impact, and economic effects over two years. Participants will be monitored through standardized data collection tools, questionnaires on satisfaction and therapeutic alliance, and interviews with professionals and families. Researchers will assess developmental outcomes at age 2, including psychomotor anomalies, and later language delays at age 4. The study aims to understand how EMPPer influences early detection, intervention, and care pathways for young children and their families over the course of the study period.

Researchers are evaluating the consistency of the EMOCARE emotional monitoring software compared to commonly used questionnaires in assessing emotional states in patients with mild to moderately severe depressive episodes. The study aims to determine whether EMOCARE provides results that align with tools like PHQ-9, MADRS, GAD-7, BDI-II, and EQ-5D-5L, and to understand patients' experiences using passive monitoring software without active involvement. This prospective, multicenter, single-blind clinical investigation focuses on adults with major depressive disorder. Participants will use the EMOCARE software on their digital devices such as smartphones or computers, with the ability to activate or deactivate it anytime during the 6-week follow-up. The study includes two scheduled visits six weeks apart, during which participants complete various questionnaires and have consultations with the doctor. Additional assessments include self-administered questionnaires at 2 and 4 weeks post-first appointment and a follow-up phone call at 3 weeks to check on participants' wellbeing. Participants are also asked to keep a diary of symptoms, medical consultations, and medication changes. Throughout the study, researchers will monitor changes in EMOCARE scores and PHQ-9 results from baseline to six weeks. Data collection includes clinical screenings, questionnaires, doctor interviews, and symptom diaries. The study focuses on understanding emotional state assessments and patient experiences over the 6-week period, ensuring participant safety and compliance with protocol requirements.

Researchers are exploring the lived experiences of people aged 15 to 30 who are at ultra-high risk (UHR) or experiencing their first episode of psychosis (FEP). The study aims to understand how these individuals experience a group-based mindfulness program and to identify any possible side effects from participating in this intervention. This qualitative study uses a phenomenological approach to gather detailed personal insights. Participants take part in a group mindfulness-based intervention designed to support those at high risk of psychosis or with early psychosis. After completing the mindfulness sessions, participants undergo a qualitative interview to share their experiences. These interviews are analyzed using the IPSE method, which helps researchers deeply understand the structure of participants' lived experiences related to mindfulness. Participants are involved in interviews conducted between one week and three months after the final mindfulness session. The study collects rich personal stories to assess the impact and safety of the intervention. The total duration of participation depends on the timing of the interview relative to the end of the mindfulness program. This approach allows researchers to capture both immediate and longer-term reflections on the mindfulness experience.

People with mental disorders tend to smoke more than the general population, which partly causes significant health differences and shorter life expectancy by 10 to 25 years. This gap is mainly due to heart and lung diseases, including bronchial cancers. Despite their motivation to quit, smoking is often overlooked or tolerated in psychiatric care, making quitting harder due to stronger withdrawal symptoms. This research evaluates a new intervention called "Tabapsy," designed with input from patients, mental health professionals, and general practitioners to support smoking cessation in adults receiving outpatient psychiatric care. The Tabapsy intervention includes a campaign to promote quitting smoking and a structured support program with multiple components: a general information meeting to boost motivation, an assessment workshop to personalize cessation plans, five thematic workshops covering treatments, emotional management, weight control, physical activity, and manual activities, plus peer support groups to encourage mutual help. A dedicated facilitator runs the program in psychiatric medical psychological centers (CMPs), supplemented by a website with resources. The study compares this intervention to usual care practices regarding smoking cessation in a cluster-randomized controlled trial involving psychiatric sectors in France. Participants are regular smokers aged 18 or older who receive outpatient psychiatric care at participating centers. They will complete questionnaires online at the start, and again at 3 and 6 months, covering smoking habits, nicotine dependence, motivation, use of quitting aids, mental and physical well-being, and knowledge about smoking. The main outcome is short-term smoking cessation lasting at least 7 days at 3 months. Secondary goals include assessing cost-effectiveness and how well the intervention is implemented. A total of 6,250 participants will be enrolled over 12 months across 22 sectors.

Researchers are investigating language disorders in patients with psychosis, including those with at-risk mental state (ARMS), first episode of psychosis (FEP), and schizophrenia. The study aims to better understand how these language difficulties, which affect many areas such as phonology, vocabulary, meaning, grammar, and communication skills, relate to other symptoms like thought disorders and neuropsychological problems. It also explores how working memory interacts with language abilities, especially syntax, in these patient groups compared to a control group. Participants will undergo a comprehensive speech and language assessment using standardized tests to evaluate language skills in both understanding and expression. Additional assessments include the Thought, Language, and Communication (TLC) scale for formal thought disorders in schizophrenia patients, the Mini International Neuropsychiatric Interview (MINI) for psychiatric evaluation of controls, and the Cannabis Abuse Screening Test (CAST) for all participants to assess cannabis use and related issues. During the study, researchers will collect data from these language and psychiatric assessments to analyze connections between language performance, neuropsychological status, and psychiatric symptoms. The primary outcome is the language assessment performance score obtained on the first day. Participants will have their clinical and psychiatric history reviewed, and their language and cognitive functions closely monitored to better characterize the nature and impact of language disorders in psychosis.